Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States | Zendy

Eric L. Ross | Zendy; Kara Zivin | Zendy; Daniel F. Maixner | Zendy

Open Access

Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States

Author(s) -

Eric L. Ross,

Kara Zivin,

Daniel F. Maixner

Publication year - 2018

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2018.0768

Subject(s) - electroconvulsive therapy , pharmacotherapy , depression (economics) , quality of life (healthcare) , psychiatry , major depressive disorder , cost effectiveness , randomized controlled trial , population , medicine , psychology , psychotherapist , mood , schizophrenia (object oriented programming) , risk analysis (engineering) , environmental health , macroeconomics , economics

Electroconvulsive therapy (ECT) is a highly effective treatment for depression but is infrequently used owing to stigma, uncertainty about indications, adverse effects, and perceived high cost.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research